QuidelOrtho Co. (NASDAQ:QDEL) Shares Purchased by WINTON GROUP Ltd

WINTON GROUP Ltd boosted its stake in shares of QuidelOrtho Co. (NASDAQ:QDEL) by 23.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 169,961 shares of the company’s stock after acquiring an additional 32,222 shares during the quarter. WINTON GROUP Ltd’s holdings in QuidelOrtho were worth $7,572,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Cerity Partners LLC purchased a new position in shares of QuidelOrtho during the 3rd quarter valued at approximately $605,000. State Street Corp increased its holdings in QuidelOrtho by 16.9% in the third quarter. State Street Corp now owns 1,907,898 shares of the company’s stock valued at $87,000,000 after buying an additional 275,522 shares in the last quarter. FMR LLC raised its position in shares of QuidelOrtho by 28.0% in the third quarter. FMR LLC now owns 1,256,356 shares of the company’s stock worth $57,290,000 after acquiring an additional 274,633 shares during the period. Merit Financial Group LLC purchased a new stake in shares of QuidelOrtho during the 4th quarter worth about $301,000. Finally, Principal Financial Group Inc. boosted its stake in shares of QuidelOrtho by 64.5% during the 3rd quarter. Principal Financial Group Inc. now owns 272,037 shares of the company’s stock worth $12,405,000 after acquiring an additional 106,642 shares in the last quarter. 99.00% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Citigroup raised QuidelOrtho from a “neutral” rating to a “buy” rating and upped their price target for the stock from $44.00 to $50.00 in a report on Wednesday, December 11th. Jefferies Financial Group assumed coverage on QuidelOrtho in a research note on Tuesday, December 10th. They set a “hold” rating and a $43.00 target price for the company. Royal Bank of Canada dropped their price target on shares of QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating on the stock in a research note on Thursday, February 13th. UBS Group boosted their price target on shares of QuidelOrtho from $43.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, February 13th. Finally, StockNews.com downgraded shares of QuidelOrtho from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, QuidelOrtho currently has a consensus rating of “Hold” and a consensus price target of $51.20.

QuidelOrtho Trading Down 0.9 %

Shares of QDEL stock opened at $35.02 on Thursday. QuidelOrtho Co. has a fifty-two week low of $29.74 and a fifty-two week high of $49.45. The firm has a market capitalization of $2.36 billion, a P/E ratio of -1.16 and a beta of 0.10. The stock’s fifty day moving average is $40.40 and its two-hundred day moving average is $41.55. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 1.22.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.44). QuidelOrtho had a positive return on equity of 3.78% and a negative net margin of 72.84%. Research analysts expect that QuidelOrtho Co. will post 2.3 earnings per share for the current fiscal year.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.